Migraleve Yellow (Paracetamol, Codeine Phosphate)

Paracetamol works by inhibiting the central synthesis of prostaglandins, which are mediators that increase pain perception and fever. By reducing prostaglandin levels in the brain, it raises the pain threshold and contributes to the overall analgesic effect when combined with codeine.

The specific dose of Migraleve Yellow is determined by the prescribing healthcare professional based on the individual’s age, medical condition, and response to therapy. Patients should follow the prescriber’s instructions and not exceed the recommended amount indicated on the product label.

Safety data for the combination of paracetamol and codeine during pregnancy or lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before using Migraleve Yellow to weigh potential benefits against possible risks.

To order Migraleve Yellow, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Migraleve Yellow combines a non‑opioid analgesic (paracetamol) with a weak opioid (codeine), offering a balance of pain relief and fewer gastrointestinal side effects compared with non‑steroidal anti‑inflammatory drugs (NSAIDs) such as ibuprofen. However, it carries opioid‑related risks, so clinicians consider patient history when choosing between options.

Store Migraleve Yellow at ambient temperature, preferably below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight and heat sources. Ensure the container is tightly closed to maintain product stability throughout its shelf life.

Migraleve Yellow is taken orally with a full glass of water. The tablet should be swallowed whole and not chewed or crushed. It is intended for adult use; children should not use this product unless specifically directed by a qualified healthcare professional.

The most serious risks include respiratory depression, especially when combined with other central nervous system depressants, severe allergic reactions such as anaphylaxis, liver injury from excessive paracetamol intake, and the potential for dependence or withdrawal symptoms related to the codeine component.

Migraleve Yellow should be avoided by individuals with known hypersensitivity to paracetamol, codeine, or any excipients in the tablet. It is also contraindicated in patients with severe respiratory depression, acute asthma attacks, or those taking monoamine oxidase inhibitors. Consultation with a healthcare professional is essential before use.